Related Experiment Video
Updated: Jan 8, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics
Manoj Dalabehera1, Arnab Ghosh2, Satyajit Mohanty3
1Department of Pharmaceutics, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, 248007, Uttarakhand, India.
Abstract:
Recent breakthroughs in mRNA therapeutics have transformed vaccine development, largely powered by lipid nanoparticle (LNP) based delivery systems. However, these systems exhibit a strong hepatic tropism, making them suboptimal for targeting extrahepatic organs such as the brain, lungs, pancreas, heart, and tumor tissues critical to non-vaccine therapeutic applications. This review explores next-generation delivery strategies designed to overcome liver centric distribution. We highlight emerging platforms, including pKa-tuned LNPs, polymeric and peptide-based carriers, exosomes, and biomimetic vesicles, along with physical enhancement techniques such as ultrasound, laser, and MRI-guided systems. Nonetheless, researchers are achieving more precise delivery to deep seated tissues by integrating these technologies with targeted ligands and responsive release mechanisms. Applications in oncology, cardiology, pulmonology, and neurology are discussed with a focus on preclinical and early clinical outcomes. Regulatory considerations, including immunogenicity, biodistribution, and manufacturing scalability, are also reviewed. Ultimately, this article presents a forward-looking perspective on engineering safe, organ specific mRNA delivery platforms beyond the liver, enabling the advancement of precision therapeutics. This review will provide a timely and comprehensive overview of innovative strategies to overcome these challenges, focusing on non-vaccine applications.
Related Concept Videos
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Regulated mRNA Transport
Drug Delivery: Enteral Route

